Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Trial Profile

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; NKTR 255 (Primary) ; PD 360324 (Primary) ; Utomilumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Giant cell tumour of tendon sheath; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JAVELIN Bladder Medley; JAVELIN Medley
  • Sponsors Pfizer
  • Most Recent Events

    • 12 Oct 2023 Results (n=40) assessing safety and efficacy of avelumab combined with utomilumab and PF-04518600 in patients with recurrent gynecologic malignancies, published in the Cancer.
    • 04 Jun 2023 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
    • 04 May 2023 Status changed from active, no longer recruiting to discontinued. The study was terminated since there was no need for further safety or efficacy data to becollected. The participants having benefit from investigational treatments have been movedto a continuation study (NCT05059522)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top